- Home
- IPEX vs CRBP Comparison
IPEX vs CRBP Comparison
Compare IPEX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPEX | CRBP |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 134.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | IPEX | CRBP |
|---|---|---|
| Price | $10.38 | $8.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | 13.3K | ★ 191.8K |
| Earning Date | 04-15-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $10.25 | $4.64 |
| 52 Week High | $10.39 | $20.56 |
Technical Indicators
Market Signals| Indicator | IPEX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 48.37 |
| Support Level | N/A | $7.45 |
| Resistance Level | N/A | $9.69 |
| Average True Range (ATR) | 0.02 | 0.65 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 83.33 | 34.04 |
Price Performance
Historical ComparisonAbout IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.